Minerva Neurosciences (NERV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board members, management, and independent auditors, and outlined meeting conduct and access to proxy materials.
Polls were opened for voting on all matters, and attendees were informed about the process for submitting questions.
Board and executive committee updates
Two Class III directors, Dr. David Kupfer and Jan van Heek, were elected to serve until the 2029 annual meeting.
Shareholder proposals
Six proposals were presented: election of directors, amendments to the certificate of incorporation (exculpation of officers and elimination of exclusive forum), advisory votes on executive compensation and its frequency, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Minerva Neurosciences
- C19 tests 64 mg roluperidone over 12 weeks, with results expected in H2 next year.NERV
Study update - Roluperidone advances in C19 toward a potential first treatment for negative symptoms.NERV
Corporate presentation - C19 advances toward 2027 data as warrant gains drive Q3 reported profit.NERV
Q3 2026 - Roluperidone targets negative symptoms of schizophrenia with strong clinical and financial backing.NERV
Corporate presentation - Roluperidone's pivotal phase III trial is on track, with results expected next year and strong investor support.NERV
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 net income was $17.5M, but a six-month net loss of $107.9M highlights funding needs.NERV
Q2 2026 - Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027.NERV
Jefferies Global Healthcare Conference 2026 - Roluperidone advances as the first late-stage therapy for negative symptoms of schizophrenia.NERV
Corporate presentation - Net loss rose to $125.4M on non-cash warrant expenses as Phase 3 roluperidone trial launched.NERV
Q1 2026